SemaThera

OverviewSuggest Edit

SemaThera is a spin-off company from AmorChem Venture Fund 1, focusing on SEMA 3A protein inhibitor in the treatment of ocular diseases, such as diabetic macular edema. This technology emerges from the laboratory of Dr Mike Sapieha, Hôpital Maisonneuve-Rosement (Montreal, Canada).
TypePrivate
Founded2016
HQMontreal-West, CA
Websitesemathera.com

Latest Updates

Employees (est.) (Sep 2019)8

SemaThera Office Locations

SemaThera has an office in Montreal-West
Show all (1)

SemaThera Financials and Metrics

Summary Metrics

Founding Date

2016

SemaThera total Funding

$1 m

SemaThera latest funding size

$1 m

Time since last funding

3 years ago
SemaThera's latest funding round in January 2017 was reported to be $1 m. In total, SemaThera has raised $1 m
Show all financial metrics

SemaThera Online and Social Media Presence

Embed Graph

SemaThera News and Updates

SemaThera Frequently Asked Questions

  • When was SemaThera founded?

    SemaThera was founded in 2016.

  • How many employees does SemaThera have?

    SemaThera has 8 employees.

  • Who are SemaThera competitors?

    Competitors of SemaThera include Harbour Antibodies, GrayBug and Rebiotix.

  • Where are SemaThera offices?

    SemaThera has an office in Montreal-West.

  • How many offices does SemaThera have?

    SemaThera has 1 office.